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S354 Poster Session IIhave amatched related donor.While transplant outcomes withHLA
matched unrelated donors continue to improve, this requires strin-
gent HLA matching which puts ethnic minorities at a disadvantage.
In this scenario, umbilical cord blood (UCB) has proven to be a valu-
able alternative source of hematopoietic stem cells as it allows for
successful engraftment and decreased GVHD for a greater degree
of HLA disparity. This is of particular importance for the Hispanic
and African American populations in theUnited States who often re-
ceive ethnically mismatched products due to low representation in
the donor pool despite increased recruitment efforts.
The St. Louis Cord Blood Bank (SLCBB) retrospectively evalu-
ated outcomes for 727 patients based on recipient/donor ethnic
match. 543 (74.7%) patients were matched and 184 (25.3%) were
not ethnically matched. Ninety two percent of all patients received
singleton cord blood transplant and 8 percent received dual cord
blood transplant with both products shipped from the SLCBB. Pa-
tient and product characteristics are presented in Table 1.
There were no differences between the groups with respect to ex-
posure to TBI, TNC dose/kg, CD34 dose/kg, and CFU dose/kg.
There was also no correlation between groups with respect to inci-
dence and severity of acute and chronic graft versus host disease
(p..05). Although the ethnically matched group had a higher degree
of HLAmatch (p\.05) time to neutrophil recovery was not impacted
(p..05; median days matched5 22, median days unmatched5 20).
Survival did not differ between the groups at 100 day and $ 1 year
time points (p..05).
This analysis supports the continued use of UCB as a source of he-
matopoietic reconstitution for all populations.
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IV BUSULFAN BASED CONDITIONING REGIMEN FOR HAPLOIDENTICAL
TRANSPLANTATION
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Introduction: Haploidentical transplant (HAPLO) offers the op-
portunity for a cure to those patients without any other available do-
nor. Following Luznik L et al experience (BBMT 2008; 14:641-650)
with a non-myeloablative schemawhere relapses were themain issue,
we developed our own conditioning model using IV busulfan (3,2
mg/kg on day -3) instead of 200cGy TBI, while maintaining post-
transplant high dose cyclophosphamide for GVHD prophylaxis on
days +3 and +4 followed by cyclosporine and MMF. Due to encour-
aging results with our initial experience, IV busulfan was increased to
3,2 mg/kg/day for 2 days in order to reduce relapse incidence and not
to increase transplant related morbidity and mortality (TRM).
Patients and Methods: From Dec-2007, 12 patients (9 males, me-
dian age 39y range 19-55) have received an HAPLO at our institu-
tion for the treatment of AML (3), ALL (1), MDS (1) Myeloma (2)
or Hodgkin’s disease (5), all of them in advanced phases of their dis-
eases. The conditioning regimen consisted of Fludarabine 30mg/m2
for 5 days, Cyclophosphamide 14,5mg/kg for 2 days and IVBusulfan
3,2 mg/kg for 1 day was used in 7 patients and 3,2 mg/kg for 2 days in
the last 5. Bone marrow was the source of progenitors in 10 and
GCSF mobilized peripheral blood without T-depletion in 2. Eight
had received a previous autologous (6) or umbilical cord blood trans-
plant (2, 1 after graft failure).
Results: Median follow up is 12.5 months (0.5-31mo). All patients
engrafted properly. Toxicities of the conditioning regimen included
grade1-2 mucositis (9) and infections (febrile neutropenia and CMV
reactivations in 11, and 1 Pseudomona vulvar cellulitis). Only 1 pa-
tient died from toxicity before day +100 (VOD/MOFat +15d, refrac-
tory ALL). AcuteGVHDgrade II-IV affected to 4/11 patients, being
grade III-IV in 2. Only 2 out of 8 cases at risk developed chronic
GVHD that was extensive in 1. After a median time of 6.5 mo
(2.5-30 mo), 7 patients are in continuous remission and 2 patients
are alive in relapse. Two patients died beyond 1 year: 1 progressive
multifocal leukoencephalopaty at +14 mo and relapse and progres-
sion of AML at +19 mo, respectively.
Conclusions: In our limited experience, IV Busulfan was well toler-
ated as part of the conditioning regimen for HAPLO. A potential re-
duction in relapse incidence without an increase in TRM would be
obtained by this approach. HAPLO is a good chance for rescueing
patients in graft failure after cord blood transplant.406
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morial Hospital, Chicago, IL; 2Northwestern University Feinberg School
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Post-transplantation chimerismmonitoring in HSCT is pivotal to
assess engraftment, rejection or relapse. There has been previous
studies performed using qrt-PCR to detect chimerism by different
technologies. Our purpose is to describe qrt-PCR as a sensitive
and reproducible method to assess chimerism using AlleleSEQR
(Cellera). A total of 112 peripheral blood samples were obtained
from 43 allogeneic HSCT. qrt-PCR (Applied Biosystems 7500)
was performed using 34 alleles that are designed to be a bi-allelic in-
sertion/deletion (indel) polymorphism in the human genome. Ex-
traction of DNA was performed using QIAamp DNA Blood Mini
Kit (Qiagen) of both donor and recipient cells pre transplant (n 5
43) then were screened for their informative alleles. At least 2 alleles
were chosen that amplified with a CT value less than 34.0, but greater
than or equal to 30.0 with aDCT of -2.0 to +2.0. Post transplant sam-
ples (n5 69) were then separated in three subsets: TotalWBC using
the Erythrocyte Lysis Buffer (Qiagen), T-cell and Myeloid cells us-
ing RosetteSep T-cell and Myeloid Enrichment kits (Stem Cell
Technologies) followed by DNA extraction and quantitation using
the chosen informative alleles. To determine the sensitivity a serial
dilution curve is shown in Table 1 with a r 5 1. Reproducibility
was validated by a reference lab using 18 unknown samples with
a correlation of r 5 0.98. Subset analysis was reported as percent
donor total: 91.9 6 2.22, median 99.6 (35.5-100), T-cell: 93.7 6
2.56, median 99.6 (29.6-100), myeloid: 91.2 6 3.23, median 99.9
(9.30-100) with a p value of\ 0.0001. Results indicate that the use
of this technology is reproducible, sensitive and accurate to assess
donor Chimerism in pediatric patients undergoing HSCT.
Table 1. qrt-PCR Sensitivity Determination
Serial Dilution qrt-PCR Results0.1% 0.086%
0.2% 0.16%
1% 1.0%
2% 1.9%
10% 9.2%407
RAPID IDENTIFICATION OF INFORMATIVE MARKERS FROM MULTIPLE
DONORS FOR STEM CELL TRANSPLANT ENGRAFTMENT MONITORING
Sigua, C.L., Santini, C.D., Bost, D.A. Celera Corporation, Alaemda, CA
Wehave designed a system of RUOqPCR assays and software en-
abling highly sensitive, stem cell engraftment monitoring. Our ap-
proach allows for facile quantification of minute amounts of minor
components in a mixture, while also reducing workflow and analysis
burdens. This approach expands the linear dynamic range over
which increasing mixed chimerism may be monitored, effectively in-
creasing the probability of detecting adverse transplant events ear-
lier.
We utilize a panel of 34 qPCR research assays to bi-allelic indels
across the genome. Our system affords rapid pre-transplant marker
identification and quantification of recipient levels post-transplant.
It enables marker identification and quantification to occur within
a few hours and without the need for capillary electrophoresis. In
an effort to decrease our current sample volume requirements, in-
crease throughput and enable multiple donor screening scenarios,
we evaluated a multiplexed assay approach for marker identification.
The qPCR assays are multiplexed, with 2-3 assays per well. The
probes are labeled with FAM-BHQ1, California Orange-BHQ1
and Quasar 670-BHQ2. The presence of alleles is scored in relation
to amplification of an endogenous control assay. The results of sam-
ples within a group are compared against each other to identify infor-
mative markers for each sample. Up to eight samples can be
